NASDAQ$RXRX
Recursion Pharmaceuticals Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Recursion Pharmaceuticals Inc reported Q2 2025 results showing revenue growth from collaborations alongside increased operating losses driven by platform expansion and the Exscientia acquisition.
The company generated $19.2 million in total revenue for the quarter, primarily from operating revenue under strategic partnerships. Net loss widened to $171.9 million due to higher research and development and general and administrative expenses. Cash and cash equivalents stood at $525.1 million at quarter end, supporting ongoing clinical and platform development.
- Total revenue reached $19.2 million, up 33% year-over-year, led by collaborative agreements with Sanofi, Roche, and Merck KGaA.
- Research and development expenses increased to $128.6 million, reflecting Tempus data purchases and post-acquisition operations.
- Net loss per share was $(0.41) on a GAAP basis with net loss of $171.9 million.
- Cash position remained strong at $525.1 million, with potential for over $100 million in partnership milestones by end of 2026.
Headline financials
Revenue & EPS history
Recursion Pharmaceuticals · Revenue · Quarterly
$19.2M
Revenue by segment
Recursion Pharmaceuticals · $19.2M total across 2 segments · Q2 2025
- Collaborative Agreements$19.1M—99.4%
- Grant Revenue$120K—0.6%
Forward guidance
Company expects potential milestone payments exceeding $100 million from partnerships by end of 2026 and continues advancing multiple programs toward development candidate status.
Tailwinds
- Multiple partnered programs advancing to development candidate decisions
- Additional neuromaps and target validation progressing with Roche/Genentech
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-3.1%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.2%
Avg return
30 days after
32%
8 / 25 earnings
Positive
+11.6%
Q1 2023
Best reaction
-16.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +1.8% | -3.3% | -1.8% | |
| Q4 2025 | +6.5% | +2.8% | -16.7% | |
| Q3 2025 | -0.6% | -9.8% | -5.8% | |
| Q1 2025 | -16.5% | -24.0% | -13.9% | |
| Q4 2024 | -12.3% | -16.9% | -29.6% | |
| Q3 2024 | +1.6% | +15.0% | +17.4% | |
| Q2 2024 | -1.3% | +2.7% | -7.1% | |
| Q1 2024 | +0.1% | +17.0% | -0.9% | |
| Q4 2023 | -12.3% | -13.2% | -32.5% | |
| Q3 2023 | -3.0% | +14.7% | +35.0% | |
| Q2 2023 | -0.5% | -13.2% | -24.2% | |
| Q1 2023 | +11.6% | +2.5% | +75.8% | |
| Q4 2022 | +7.1% | +11.4% | -11.3% | |
| Q3 2022 | +8.9% | +32.8% | -0.6% | |
| Q2 2022 | +4.4% | +27.4% | +35.8% | |
| Q1 2022 | -9.4% | +1.4% | +34.4% | |
| Q4 2019 | -0.7% | -1.7% | -14.2% | |
| Q4 2021 | -0.7% | -1.7% | -14.2% | |
| Q3 2021 | -9.1% | -4.3% | -3.2% | |
| Q3 2020 | -9.1% | -4.3% | -3.2% | |
| Q2 2021 | -10.8% | -17.2% | +23.1% | |
| Q2 2020 | -10.8% | -17.2% | +23.1% | |
| Q4 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2021 | -7.1% | -3.6% | +37.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro